Clinical Trial Update: NTI164 in Autism Spectrum Disorder [Phase 3]

View source ↗

Summary

NTI164 is a Phase 3 trial for Autism Spectrum Disorder that has not yet begun recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autism Spectrum Disorder

Drugs mentioned

• NTI164

Snippet

Sponsor: Fenix Innovation Group | Conditions: Autism, Autism Spectrum Disorder | Phase 3 | Status: NOT_YET_RECRUITING